Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy

• Published in: Journal of internal medicine 2018-02, Vol.283 (2), p.110-120
• Main Authors: Chowdhury, P. S., Chamoto, K., Honjo, T.
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Apoptosis; Augmentation; B-Lymphocytes - immunology; Cancer; Cancer immunotherapy; Cancer therapies; Chemotherapy; Clinical trials; combination therapies; Combined Modality Therapy; CTLA-4 protein; Drug discovery; Energy metabolism; FDA approval; Humans; Immune checkpoint; Immune response; Immune system; Immunotherapy; Immunotherapy - methods; Lymphocytes; Lymphocytes T; Medical research; Metabolism; Mitochondria; mitochondrial energy metabolism; Neoplasms - drug therapy; Neoplasms - radiotherapy; Neoplasms - therapy; PD-1 protein; PD-L1 protein; PD‐1 blockade; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Radiation; Radiation therapy; Regulatory mechanisms (biology); T cell; T-Lymphocytes - immunology; Tumors
• ISSN: 0954-6820; 1365-2796
• DOI: 10.1111/joim.12708

Programmed death 1 (PD‐1) is an immune checkpoint molecule that negatively regulates T‐cell immune function through the interaction with its ligand PD‐L1. Blockage of this interaction unleashes the immune system to fight cancer. Immunotherapy using PD‐1 blockade has led to a paradigm shift in the field of cancer drug discovery, owing to its durable effect against a wide variety of cancers with limited adverse effects. A brief history and development of PD‐1 blockade, from the initial discovery of PD‐1 to the recent clinical output of this therapy, have been summarized here. Despite its tremendous clinical success rate over other cancer treatments, PD‐1 blockade has its own pitfall; a significant fraction of patients remains unresponsive to this therapy. The key to improve the PD‐1 blockade therapy is the development of combination therapies. As this approach has garnered worldwide interest, here, we have summarized the recent trends in the development of PD‐1 blockade‐based combination therapies and the ongoing clinical trials. These include combinations with checkpoint inhibitors, radiation therapy, chemotherapy and several other existing cancer treatments. Importantly, FDA has approved PD‐1 blockade agent to be used in combination with either CTLA‐4 blockade or chemotherapy. Responsiveness to the PD‐1 blockade therapy is affected by tumour and immune system‐related factors. The role of the immune system, especially T cells, in determining the responsiveness has been poorly studied compared with those factors related to the tumour side. Energy metabolism has emerged as one of the important regulatory mechanisms for the function and differentiation of T cells. We have documented here the recent results regarding the augmentation of PD‐1 blockade efficacy by augmenting mitochondrial energy metabolism of T cell.